Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma.
about
CpG Oligonucleotides as Cancer Vaccine AdjuvantsEpithelial toll-like receptor 9 signaling in colorectal inflammation and cancer: clinico-pathogenic aspectsImmune Adjuvant Effect of Molecularly-defined Toll-Like Receptor LigandsSafety of Toll-like receptor 9 agonists: a systematic review and meta-analysis.Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity.Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects.Toll-like receptor agonists in cancer therapy.Non-clinical safety studies of IMT504, a unique non-CpG oligonucleotide.Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.Toll-like receptor agonists: are they good adjuvants?In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II studyEarly development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers.Optimizing dendritic cell-based approaches for cancer immunotherapyIntralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancerRole of plasmacytoid dendritic cells and inducible costimulator-positive regulatory T cells in the immunosuppression microenvironment of gastric cancer.Targeting the tumor microenvironment to enhance antitumor immune responsesEfficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis.Cancer and the microbiome: potential applications as new tumor biomarker.Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapyIntratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cellsInvolvement of Toll-like Receptor 9 polymorphism in cervical cancer developmentImmunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial.Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment.Trial Watch: Experimental Toll-like receptor agonists for cancer therapyEffect of CpG ODN on monocytic myeloid derived suppressor cells.Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in miceImmunotherapy for melanoma: current status and perspectives.Oligodeoxynucleotides expressing polyguanosine motifs promote antitumor activity through the upregulation of IL-2.High efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors.Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor modelsPlasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cellsImmunotherapeutic approaches to hepatocellular carcinoma treatmentImmune adjuvant effect of a Toxoplasma gondii profilin-like protein in autologous whole-tumor-cell vaccination in mice.Toll-like receptor 9 agonists as cancer therapeutics.Stimulating natural killer cells to protect against cancer: recent developments.Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?Prophylactic and therapeutic implications of toll-like receptor ligands.Immunotherapy in nonmelanoma skin cancer.Toll-like receptors in human papillomavirus infection.Tremelimumab: a review of development to date in solid tumors.
P2860
Q26783826-13DDC7FD-E05A-44D5-A100-DBC0767D12EBQ27025290-09790AFB-C620-4948-9255-198E52B01ADAQ28972540-42A87426-94F9-4062-84EC-5CEE2F5002D6Q33413438-D241D6FD-2BB0-4935-9522-95B0329AF2E6Q33690978-33919318-76B7-4958-88E2-CFC8451B8D00Q33801802-DB905405-5C3E-46CD-A3D5-3CFC07959334Q33918509-620E23DF-ED0F-4924-9CA2-804A198FE4FDQ33931430-8A96C6D8-B224-4C6E-AB27-661B9B68165CQ33960866-031B35D6-EFB7-4C51-ABB8-35AE81508ED3Q34067537-E9BAFDCF-C613-497F-9969-057B67876DFEQ34194680-967946C8-1823-41E6-B508-19DC93E14878Q34619324-8A91D446-8ACB-4838-BB64-6F8C8E3C0095Q34637535-89E0F8D6-DFB1-455F-861E-B0767F2B54CEQ34849409-863DC8B7-0AF8-4D2D-B2D2-96025CE5A568Q35051504-82FAE07E-DA58-4D39-8B44-F9C03903F21AQ35176307-C90B12A4-92A1-4D90-B04C-5B080C26AEC4Q35231246-E99FBCEF-F72C-404E-BDBA-F14C829F43C9Q35508820-79126746-00BE-43D2-BF90-9627AD3C5FDDQ35721553-87641AC5-E667-4C6C-ADD6-D2B68F3AA813Q35740077-BB119353-AE3A-4156-A9B2-271528BE4063Q36060845-4F2F94E7-EB04-4E80-874D-1C7344D4AB22Q36092885-956A7C3B-40FA-4765-806E-70B62168367BQ36107932-7DDAFA0A-5CC4-46CD-B9E5-ACFF559E253BQ36194849-1D021309-4B8F-43BA-9663-9BBD04B4F551Q36194871-AFE842C2-F64E-4B4F-AF7B-5A78900F7780Q36403509-6FB66F90-91A4-4997-B35F-C9D99A99236BQ36453216-2811722A-65D0-47D8-9F84-16B56D56220AQ36586115-6118310C-8E32-4F03-A5BB-94937B45C5FEQ36608597-5AC29304-69F0-488B-861B-3B2A5066C2A0Q36827406-BD43B3B4-9B64-4A08-A87F-4087ECB5A8F3Q36839509-F6648850-84D1-4A44-B405-6D66878543C2Q37140685-C7604F9B-5795-4F22-95F0-E4AAA1A3C539Q37687530-3407E762-7ACD-407D-B341-B303646812D4Q37831323-DA31B824-7605-4F49-AF55-DA2D07E05098Q37877269-805A9767-ED17-43F6-86CB-7562BD43A15CQ37952804-0AC7BE03-774A-46CD-8978-07050C3BD1FFQ37989884-2B203984-56DB-48F8-9645-DCA01878BC8FQ38014084-1CFCE175-03AB-4E6A-8A38-D0F955004C6DQ38084160-385E6A66-3329-4F3C-A996-85A1CD27FBA8Q38085028-18DC8257-3839-4105-A7D8-BFFC19152605
P2860
Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Phase 1 evaluation of intrales ...... cinoma or metastatic melanoma.
@en
Phase 1 evaluation of intrales ...... cinoma or metastatic melanoma.
@nl
type
label
Phase 1 evaluation of intrales ...... cinoma or metastatic melanoma.
@en
Phase 1 evaluation of intrales ...... cinoma or metastatic melanoma.
@nl
prefLabel
Phase 1 evaluation of intrales ...... cinoma or metastatic melanoma.
@en
Phase 1 evaluation of intrales ...... cinoma or metastatic melanoma.
@nl
P2093
P1476
Phase 1 evaluation of intrales ...... cinoma or metastatic melanoma.
@en
P2093
Christian Kors
Heike Audring
Maja A Hofmann
Peter Walden
Uwe Trefzer
Wolfram Sterry
P304
P356
10.1097/CJI.0B013E318174A4DF
P577
2008-06-01T00:00:00Z